Dateline City:
BOSTON
Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease
Collaboration Includes a $1 Billion Up-front Payment by Merck to Bayer
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that it has entered into a definitive agreement to sell
its Merck Consumer Care (MCC) business to Bayer AG (BAYRY) for $14.2
billion. Under the terms of the agreement, Bayer AG will acquire Mercks
existing OTC business, including the global trademark and prescription
rights for Claritin and Afrin.
Language:
English
Contact:
MerckMedia:Steve Cragle, 908-423-3461Pam Eisele, 267-305-3558orInvestors:Joe Romanelli, 908-423-5185Carol Ferguson, 908-423-4465
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more